Teva Pharmaceutical Industries TEVA shares are buying and selling decrease Wednesday on the heels of the corporate’s fourth-quarter monetary outcomes. Right here’s what it’s worthwhile to know.
What To Know: Teva reported fourth-quarter income of $4.2 billion, beating analyst estimates of $4.13 billion, in keeping with Benzinga Professional. The corporate reported fourth-quarter adjusted earnings of 71 cents per share, beating estimates of 70 cents per share.
“Specializing in rigorous execution of our Pivot to Progress technique all year long, we continued to realize vital milestones in every of its 4 pillars, together with surpassing the outlook for our key revolutionary merchandise, rising our generics enterprise throughout all segments, and accelerating our early-stage revolutionary pipeline, together with the optimistic Part 2b outcomes for our duvakitug (anti-Tl1A) asset,” stated Richard Francis, president and CEO of Teva Pharmaceutical.
“These outcomes pave the way in which for pivotal trials in Crohn’s illness and ulcerative colitis, in addition to, probably, different Immunological and fibrotic indications past, in collaboration with our companion, Sanofi.”
Verify This Out: Danaher This fall: EPS Miss Expectations Amid Diagnostics Phase Lag
Outlook: Teva Pharmaceutical expects full-year 2025 income to be within the vary of $16.8 billion to $17.4 billion versus estimates of $17.05 billion. The corporate expects full-year adjusted earnings to be between $2.35 and $2.65 per share versus estimates of $2.79 per share.
“In 2025, we anticipate additional progress in our key revolutionary development drivers, whereas additionally executing on our complicated generics and biosimilars enterprise, supported by new product launches. We’re additionally excited to advance to Part 3 trials for our duvakitug (anti-TL1A) asset,” Francis stated.
The corporate’s earnings steerage seems to be weighing on shares. Administration is at present discussing the quarter on a convention name that kicked off at 8 a.m. ET.
TEVA Worth Motion: Teva Pharmaceutical shares have been down 8.78% at $19.64 on the time of publication, in keeping with Benzinga Professional.
Picture: courtesy of Teva Pharmaceutical.
Market Information and Information delivered to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
